(1R,2S,3R,5R)-3-{7-[(1R,2S)-2-phenyl-cyclopropylamino]-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl}-5-(1H-tetrazol-5-yl)-cyclopentane-1,2-diol | 1022944-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: (1R,2S,3R,5R)-3-{7-[(1R,2S)-2-phenyl-cyclopropylamino]-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl}-5-(1H-tetrazol-5-yl)-cyclopentane-1,2-diol
• 英文别名: (1R,2S,3R,5R)-3-[7-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2H-tetrazol-5-yl)cyclopentane-1,2-diol
• CAS: 1022944-94-0
• 化学式: C₂₂H₂₆N₁₀O₂S
• 分子量: 494.58
• InChiKey: SAVVNOCOOLKEPU-SSDGSGIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  189
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (1R,2S,3R,5R)-3-{7-[(1R,2S)-2-phenyl-cyclopropylamino]-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl}-5-(1H-tetrazol-5-yl)-cyclopentane-1,2-diol 在 氢氧化钾 作用下， 以 水 为溶剂， 生成 (1R,2S,3R,5R)-3-{7-[(1R,2S)-2-phenyl-cyclopropylamino]-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl}-5-(1H-tetrazol-5-yl)-cyclopentane-1,2-diol potassium salt
  参考文献：
  名称：

  Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists

  摘要：

  本发明涉及一种新颖的双环三唑嘧啶化合物，其化学式为(I)或其形式：其中R1和R2如本文所定义，以及它们的制备方法和作为ADP抑制剂的用途。

  公开号：

  US20080108635A1
• 作为产物：
  描述：

  3-[(3aS,4R,6R,6aR)-2,2-dimethyl-6-(2H-tetrazol-5-yl)-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]-N-[(1R,2S)-2-phenylcyclopropyl]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-7-amine 在 水 、 三氟乙酸 作用下， 以59%的产率得到(1R,2S,3R,5R)-3-{7-[(1R,2S)-2-phenyl-cyclopropylamino]-5-propylsulfanyl-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl}-5-(1H-tetrazol-5-yl)-cyclopentane-1,2-diol
  参考文献：
  名称：

  Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists

  摘要：

  本发明涉及一种新颖的双环三唑嘧啶化合物，其化学式为(I)或其形式：其中R1和R2如本文所定义，以及它们的制备方法和作为ADP抑制剂的用途。

  公开号：

  US20080108635A1

文献信息

• Methods of modulating immune activity
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US11376272B2

  公开（公告）日：2022-07-05

  In one aspect, the invention provides methods of increasing immune response by administering postcellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist.

  一方面，本发明提供了通过施用暴露于应激条件下的细胞产生的细胞后信号因子来提高免疫应答的方法。在一个方面，本发明提供了通过联合施用(a)干扰素基因刺激剂（STING）激动剂和(b)嘌呤能受体激动剂来增加免疫反应的方法。免疫反应的增强可用于治疗感染或癌症等。本发明还提供了筛选测定法，用于鉴定能诱导产生细胞后信号因子的化合物，这些细胞后信号因子也是免疫刺激剂。本发明进一步提供了鉴定具有免疫刺激活性的细胞后信号因子的方法。在另一方面，本发明提供了通过向细胞、组织或受试者单独施用嘌呤能受体拮抗剂或与干扰素基因刺激剂（STING）拮抗剂联合施用来降低免疫反应的方法。
• TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS
  申请人：Janssen Pharmaceutica NV

  公开号：EP2081433A2

  公开（公告）日：2009-07-29
• METHODS OF MODULATING IMMUNE ACTIVITY
  申请人：Flagship Pioneering Innovations V, Inc.

  公开号：US20210299155A1

  公开（公告）日：2021-09-30

  In one aspect, the invention provides methods of increasing immune response by administering posteellular signaling factors produced by cells exposed to a stress condition. In one aspect, the invention provides methods of increasing immune response by administering in combination (a) a Stimulator of Interferon Genes (STING) agonist and (b) a purinergic receptor agonist. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce production of postcellular signaling factors which are also immunostimulatory agents. The invention further provides methods for identifying postcellular signaling factors with immunostimulatory activity. In another aspect, the invention provides methods of decreasing immune response by administering to a cell, tissue or subject a purinergic receptor antagonist alone or in combination with a Stimulator of Interferon Genes (STING) antagonist.
• US7566722B2
  申请人：——

  公开号：US7566722B2

  公开（公告）日：2009-07-28
• [EN] TRIAZOLOPYRIMIDINE DERIVATIVES AS ADP P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIMIDINE CONVENANT COMME ANTAGONISTES DU RÉCEPTEUR P2Y12 DE L'ADP
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2008054795A2

  公开（公告）日：2008-05-08

  [EN] The present invention is directed to novel bicyclic triazolopyrimidine compounds of Formula (I) or a form thereof, wherein R₁and R₂ are as defined herein, and their methods of preparation and use as ADP inhibitors.
  [FR] La présente invention concerne de nouveaux composés bicycliques de la triazolopyrimidine représentés par la formule (I) ou l'une de ses formes. Dans cette formule, R₁ et R₂ sont tels que définis dans la description. L'invention concerne également les procédés d'élaboration correspondants et leur utilisation comme inhibiteur de l'adénosine 5'-diphosphate (ADP).